Evidence map›Paper›PMID 26314708›Full record

ArticleGenes & development2015

Regulation of gene expression dynamics during developmental transitions by the Ikaros transcription factor.

Teresita L Arenzana, Hilde Schjerven, Stephen T Smale

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & development, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Transcriptional network dynamics in early T cell development.The Journal of experimental medicine · 2024
    Review
  6. Ikaros is a principal regulator of AireScience immunology · 2023
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. CHD4 is essential for transcriptional repression and lineage progression in B lymphopoiesis.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  13. The Tale of CHD4 in DNA Damage Response and Chemotherapeutic Response.Journal of cancer research and cellular therapeutics · 2019
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. The Ikaros family of zinc-finger proteins.Acta pharmaceutica Sinica. B · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Teresita L ArenzanaDepartment of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California 90095, USA;
Hilde SchjervenDepartment of Laboratory Medicine, University of California at San Francisco, San Francisco, California 94143, USA.
Stephen T SmaleDepartment of Microbiology, Immunology, and Molecular Genetics, University of California at Los Angeles, Los Angeles, California 90095, USA;
University of California, Los Angeles · USUniversity of California, San Francisco · US

Funding

REGULATION OF TDT EXPRESSION DURING LYMPHOPOIESISR01DK043726 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SMALE, STEPHEN T · 1996 to 2014
$4.2M
Training in Developmental HematologyT32HL086345 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KOHN, DONALD B · 2007 to 2022
$3.8M
NHLBI NIH HHS T32 HL086345NIDDK NIH HHS R01 DK043726NIDDK NIH HHS R01 DK43726
6 · The paper itself

Abstract

The DNA-binding protein Ikaros is a potent tumor suppressor and hematopoietic regulator. However, the mechanisms by which Ikaros functions remain poorly understood, due in part to its atypical DNA-binding properties and partnership with the poorly understood Mi-2/NuRD complex. In this study, we analyzed five sequential stages of thymocyte development in a mouse strain containing a targeted deletion of Ikaros zinc finger 4, which exhibits a select subset of abnormalities observed in Ikaros-null mice. By examining thymopoiesis in vivo and in vitro, diverse abnormalities were observed at each developmental stage. RNA sequencing revealed that each stage is characterized by the misregulation of a limited number of genes, with a strong preference for stage-specific rather than lineage-specific genes. Strikingly, individual genes rarely exhibited Ikaros dependence at all stages. Instead, a consistent feature of the aberrantly expressed genes was a reduced magnitude of expression level change during developmental transitions. These results, combined with analyses of the interplay between Ikaros loss of function and Notch signaling, suggest that Ikaros may not be a conventional activator or repressor of defined sets of genes. Instead, a primary function may be to sharpen the dynamic range of gene expression changes during developmental transitions via atypical molecular mechanisms that remain undefined.

Indexed as

AnimalsCarrier ProteinsCell Cycle CheckpointsCell DifferentiationCells, CulturedDNA-Binding ProteinsFemaleGene Expression Regulation, DevelopmentalIkaros Transcription FactorMaleMiceNerve Tissue ProteinsReceptor, Notch1Sequence Analysis, RNAThymocytesCarrier ProteinsDNA-Binding ProteinsIkaros Transcription FactorNerve Tissue ProteinsReceptor, Notch1Zfpn1a1 protein, mouseZfpn1a4 protein, mousegene regulationIkarosleukemogenesislymphocyte developmenttranscription

Identifiers

PMID26314708
PMCPMC4573854
OpenAlexW2133673427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.